BioLineRx Ltd.

Ladies and gentlemen, thank you for standing by. The conference will begin shortly. Ladies and gentlemen, thank you for standing by. Welcome to the BioLine Rx third quarter 2025 financial results conference call. All participants are presently in a listen-only mode. Following management's formal presentation, instructions will be given for the question and answer session. For operator assistance during the conference, please press star zero. As a reminder, this conference is being recorded. I would now like to turn over the call to Irina Kostler, Investor Relations. Irina, please go ahead.

Thank you, Operator, and welcome, everyone. Thank you for joining us on our quarterly results conference call. Earlier today, we issued a press release, a copy of which is available in the Investor Relations section of our website. It was also filed as a 6K. I'd like to remind you that certain statements we make during the call will be forward-looking. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 20F and our quarterly reports on Form 6K that are filed with the U.S. Securities and Exchange Commission. At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BioLineRx.

Thank you, Irina, and good morning, everyone. And thank you for joining us on today's call. turning the call over to Molly Zevi, our Chief Financial Officer, to briefly recap our financials. Afterwards, we will take your questions. Ella Serrani, our Chief Development Officer, is also available for Q&A. I would like to begin this morning with a recap of our very significant and transformational announcement that we established a JV with Hemispherian, a Norwegian privately held biotech company, to develop GLIX-1, a highly innovative molecule for the treatment of glioblastoma and other cancers. The JV combines our proven track record of clinical and regulatory success, with hemispherian's expertise in small molecule cancer drug discovery, specifically in the area of DNA damage response research that leverages a unique mechanism of action that targets cancer cells. With these complementary capabilities, I believe we are very well positioned to bring much needed innovation to the most challenging cancer types while creating long-term value for our respective shareholders. Glix-1 is a first-in-class oral small molecule. As mentioned, Glix-1 is a very innovative molecule with a unique mechanism of action that targets DNA damage response in cancer cells while sparing healthy cells. Based on this unique MOA, the fact that it crosses the blood-brain barrier as well as highly impressive preclinical results, the first indication to be investigated will be glioblastoma or GBM, both newly diagnosed and recurrent. The FDA cleared hemispherians IND in August, and with the JV now up and running, we are planning to initiate a first in human phase 1, 2A glioblastoma trial in the first quarter of next year. At the same time, GLIX-1 is a versatile molecule that has shown compelling anti-tumor activity in a large variety of cancer cell lines and other cancer models as well, and we will continue to advance preclinical activities in support of potential trials and other high unmet needs cancer indications. Briefly recapping the terms of the JV agreement, hemispheric percent of the JP's share capital and BioLine holds 40 percent. We will continue to increase our stake over time up to a 70 percent stake as we continue to invest additional capital into the program. The unmet need in glioblastoma is significant. It is the most common and aggressive form of primary brain cancer. The current standard of care treatment was established more than 20 years ago with only limited improvements since that time. Treatment includes surgical resection, followed by radiotherapy and concomitant and adjuvant chemotherapy, but the prognosis for patients is poor, with median survival of approximately 12 to 18 months following diagnosis. GBM occurs at all ages, but peaks with individuals in their 50s and 60s, with an increasing incidence driven by an aging global population. New and better treatments are desperately needed that can improve survival, maintain quality of life, and delay tumor progression. By 2030, the annual incidence of GBM is expected to be approximately 18,500 patients in the U.S. and approximately 13,400 across the EU 4 plus 1, France, Germany, Italy, Spain, and the U.K. This translates into total addressable markets across both the newly diagnosed and recurrent settings of more than $3.7 billion in the U.S. and Europe alone. We view this as a wide-open market with few competitors. In terms of next steps, as mentioned, Glix1's IND was cleared by the FDA this past August, and we are planning to initiate Data from the phase one part of the trial is anticipated in the first half of 2027, but we may provide periodic updates earlier. Notably, two renowned experts in the area of glioblastoma, Dr. Roger Stoop and Dr. Dita Primdahl of the Malnati Brain Tumor Institute at Northwestern University, will serve as principal investigators for the study. We already talked about Glix-1's unique mechanism of action as well as the fact that we believe this novel molecule has potential clinical utility across a range of cancers. To that end, we were very pleased to announce just a few days ago that we received a notice of allowance from the USPTO for a key patent covering the use of Glix-1 for the treatment of all cancers in which cytidine deaminase, or CDA, is not overexpressed beyond a specific threshold. It is estimated that as many as 90% of all cancers, both solid tumor and hematological cancers, fall into this category, and we have already seen potent anti-tumor activity in other cancer models in which GLIX-1 has been evaluated. So while glioblastoma is our lead indication, as previously mentioned, we are planning to expand the development of GLIX-1 into additional cancer indications. We believe the versatility of GlixOne provides us with multiple opportunities to advance cancer patient care while creating value for our company. Importantly, this new patent broadens and strengthens GlixOne's patent protection until 2040 with a possible patent term extension of up to five years. In addition to the recently allowed U.S. patent just referenced, GLIX-1 is covered by two additional key patent families covering its use alone and in combination with established anti-cancer agents. GLIX-1 for use in treating cancer of the central nervous system, such as glioblastoma, is covered by patents issued in the U.S., Europe, and 13 other countries. The patents are valid until at least 2040 with a possible patent term extension of up to five years. And then Glix-1 in combination with PARP inhibitors for use in treating homologous recombination proficient cancers, which represent the majority of cancers, is covered by a pending international patent application. Corresponding national-based patents, if granted, will be valid until at least 2044, with a possible patent term extension of up to five years. So we are very pleased to have brought this highly innovative molecule into our pipeline, and we look forward to keeping you apprised of our progress as we pursue its development in a range of very challenging cancers. Turning now to pancreatic cancer, or PDAC, recall that we retained the rights to develop a tixoportide in PDAC as part of the ARAMID-OUT licensing agreement, and we continue to support its ongoing development in this indication. A randomized phase 2B clinical trial sponsored by Columbia University and supported by both Regeneron and BioLine RX, known as Chemo4MetPank, continues to enroll patients. The Chemo4MetPank trial is evaluating metixifortide in combination with the PD-1 inhibitor, Simiplibab, and standard chemotoxins. A pre-specified interim analysis is planned for when 40% of progression-free survival events are observed. Results for this trial of positive can be a significant value inflection point for our company and signal new hope for patients suffering from this very challenging tumor type. We look forward to keeping you up to date on our progress with this important program. In terms of cash, Our balance sheet remains strong. We ended the third quarter with cash and equivalents of approximately $25.2 million, which is sufficient to fund our operating plan as currently contemplated into the first half of 2027. We also have the potential benefit of royalties and milestone-driven revenue from our license agreements with both AirMid and Gloria Biosciences. Our goal continues to be to help as many patients as possible while creating enduring value for our shareholders. Before turning the call over to Molly to review our financials in more detail, I'd like to briefly touch on FX's performance in the third quarter. The AirMed team continues to make progress driving FX to adoption, generating sales of $2.4 million in Q3 2025, which resulted in $0.4 million of royalty revenue to BioLine RX. We remain optimistic about the role that Effecsta can play in the new multiple myeloma treatment paradigm and look forward to meaningful growth from this next generation stem cell mobilization agency. Recall that when we executed the Eramid Outlicensing Agreement last year, they obtained not only the rights to commercialize Effecsta in stem cell mobilization for multiple myeloma, but also the rights to develop metixifortide across all other indications, excluding solid tumor indications, and in all territories other than Asia. This includes the evaluation of metixifortide in sickle cell disease. A phase one investigator-initiated trial sponsored by Washington University School of Medicine recently concluded, and we are very pleased to announce that an abstract detailing final positive results from this proof of concept study has been accepted taking place December 6th to December 9th. Hitting a few of the highlights, the trial, which enrolled 10 subjects, evaluated montixifortide both as monotherapy and in combination with natalizumab for the mobilization of hematopoietic stem cells for gene therapies in sickle cell disease. The study demonstrated that montixifortide alone and in combination In addition, Motixifortide alone and in combination with Natalizumab demonstrated robust hematopoietic stem cell mobilization to the peripheral blood, resulting in high collection yields. Furthermore, in two subjects who had previously undergone mobilization with Florixifor, Motixifortide alone and in combination with Natalizumab resulted in nearly 3x greater mobilization and subsequent collection yields. In conclusion, this trial demonstrated the potential of metixiportide alone and in combination with natalizumab as a novel GCSF-free regimen to safely optimize hematopoietic stem cell mobilization in sickle cell disease. These results strongly support continued development in this indication. The current standard of care mobilization agent, GCSF, is contraindicated in patients for an agent that can reliably produce the very large quantities of stem cells that manufacturing and transplantation require in this indication, around 20 million CD34 positive cells per kilogram, without further burdening the already constrained apheresis capacity. We believe Motixifortide has the potential to expand access to stem cell mobilization and transplantation in sickle cell disease, which is potentially curative for these patients. Now let me turn the call over to Molly to provide a financial update. Molly, please go ahead.

Thank you, Phil. As is our practice, I will only go over the most significant items in our financial statements. Revenues, cost of revenues, research and development expenses, sales and marketing expenses, net loss, and cash. I invite you to review the 6K that we filed this morning, which contains our financials and press releases. Total revenues for the third quarter of 2025 were $0.4 million, reflecting the royalties paid by Airmid from the commercialization of Affecta in stem cell mobilization in the U.S. Cost of revenues for the third quarter of 2025 was immaterial. Both revenues and cost of revenues in 2025 are not comparable to the same period in 2024. which primarily reflect the portion of the upfront payment received by us under the Gloria License Agreement, as well as direct commercial sales of Afeksta by BioLineRx prior to the Airmid transaction in November 2024. Research and development expenses for the third quarter of 2025 were $1.7 million, compared to $2.6 million for the third quarter of 2024. The decrease resulted primarily from lower expenses related to Motexa Fortides, following the out-licensing of U.S. rights to EIRMID, as well as a decrease in payroll and share-based compensation, primarily due to a decrease in headcount. There were no sales and marketing expenses for the third quarter of 2025, compared to $5.5 million for the third quarter of 2024. The decrease resulted primarily from the shutdown of our U.S. commercial operations in the fourth quarter of 2024 following the Airmint Outlicensing transaction. General and administrative expenses for the third quarter of 2025 were $0.8 million compared to $1.4 million for the third quarter of 2024. The decrease resulted primarily from lower payroll and share-based compensation, primarily due to a decrease in headcount as well as small decreases in a number of general and administrative expenses. Net loss for the third quarter of 2025 was $1 million, compared to net loss of $5.8 million for the third quarter of 2024. As of September 30, 2025, the company had cash, cash equivalents, and short-term bank deposits of $25.2 million sufficient to fund operations as currently planned, into the first half of 2027. And with that, I'll turn the call back over to Phil.

Thank you, Molly, and thank you to everyone joining this call. Operator, we will now open the call to questions.

Thank you. Ladies and gentlemen, at this time, we will begin the question and answer session. If you have a question, please press star 1. If you wish to cancel your request, please press star 2. If you are using speaker equipment, kindly lift the handset before pressing the numbers. Your questions will be pulled in the ordinary seat. Please stand by while we pull for your questions. The first question is from Joe Pangenis of HC Wainwright. Please go ahead.

Hi everybody, good morning and good afternoon. Thanks for taking the questions. If you don't mind, I'm gonna ask all three of my questions at the same time because this is background noise, so please bear with me. So first, I wanted to get a sense, as we look towards the upcoming clinical study for Blix1, As you look early on for PK and PD markers, are there any potential PD markers that you'd look to release that might be correlative with clinical activity as people look to tease out any additional information from the study, number one? Number two, what would you say your intermediate or longer-term needs are for manufacturing capacity for Blix-1? And number three, thank you for taking these. As you look towards additional information tumor indications, when do you think we might see some preclinical data readouts and what those indications might be? Thanks a lot.

Thanks, Joe. So first of all, good morning, and thanks for joining the call. Ella, do you want to take the question?

Yes, sure. Hi, Joe. Thanks for your question. So the first question with regard to PK and PD markers during the clinical trial of CLICS. PK is an easy one. Of course, we are planning to take extensive PK data during this trial. With regard to pharmacodynamic markers, we do have pharmacodynamic markers for GLEX1. However, they are from biopsies. And since we are talking in the first part, at least, of the study about recurrent GBMs, biopsies during or following treatment will not be easy to be obtained. Having said that, if there are going to be surgeries along the trial, then we are planning to use those in order to get some input with regards to these biomarkers. I hope this answers the question.

Yeah, thank you. And as far as the intermediate manufacturing at a world-class CDMO, we don't anticipate any need to change manufacturers or whatever. I think the current manufacturer has more than enough capacity, and the batch size is correct for us to move forward all the way to Phase 2A.

And regarding your third question on results of preclinical models, so we are performing then with regards to when we will be able to present results, probably in, well, the plan would be in one of the conferences next year.

Thanks for that. All right, Joe. Thanks very much. Have a good day.

The next question is from John Vandermosten of Lux. Please go ahead.

Thank you. So why the activities that commercialize effects are responsible, Ahmed, I wanted to see if you can help me think about like a medium-term target for market penetration based on today's vantage point. Is that something you can help me with, Phil?

We can't really help you with it. You know, we're no longer, you know, the owners, so to speak, of the market. in the territories that Aramid, you know, holds. And so we're not really giving guidance at this time since it's no longer a product. I wish I could, you know, give you a better answer than that, but I'm really not able to.

Okay. And then shifting on to GBM, what would be a reasonable target for an improvement in overall survival for GBM that would you know, get established pharma interested and get the FDA to be on board with approval. I know, again, that's well down the road, but I was wondering what you had in mind in terms of what would be material enough to get all parties, all stakeholders interested.

Yeah, hi. So with regards to that, I think it depends, of course, if you're talking with current GBM or newly diagnosed GBM. I think for the newly diagnosed GBM, the benchmark would be, I mean, temozolomide was approved based on improvement of median overall survival of approximately two and a half months, so that would probably be sufficient in terms of improvement of overall survival for newly diagnosed GBM. For recurrent GBM, I think the bar would even be lower in terms of improved efficacy.

Okay, that's very helpful. And then just that question on the financial statements. So your investments in the JV, how will they appear on your financial statements? Is that considered an R&D expense or will it end up somewhere else? I know there's a few different components there, like a periodic piece and then the investments in the JV itself.

Yeah, so we ultimately control the JV. We have control of the board of directors, and we also have control of the joint development committees, et cetera. So we're actually consolidating the JV in our financial statements, and so therefore all of the expenses in the JV will be reflected in the specific financial statement line items as it

Okay, so those are all considered R&D expense, including that, I think, that $80,000 amount?

Yes, of course, yes. That $80,000 amount actually is for specific services, transition services, and what have you. So it will all be reflected in R&D expenses. I believe you're correct. Great. All right. Thank you, Phil. All right. Have a great day, John.

If there are any additional questions, please press star 1. If you wish to cancel your request, please press Start To. Please stand by while we pull for your questions. There are no further questions at this time. Mr. Serling, would you like to make a concluding statement?

Yes, I would. Thank you, Operator. In closing, we remain very excited about this new vision for BioLine RX. challenging cancer types. I am very excited about what the future holds for BioLine Rx in 2026 and beyond. Thank you all very much for your continued interest in BioLine Rx.